Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $448.18 million. The enterprise value is $775.93 million.
| Market Cap | 448.18M |
| Enterprise Value | 775.93M |
Important Dates
The next estimated earnings date is Tuesday, November 4, 2025, before market open.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 66.89 million shares outstanding. The number of shares has increased by 5.89% in one year.
| Current Share Class | 66.89M |
| Shares Outstanding | 66.89M |
| Shares Change (YoY) | +5.89% |
| Shares Change (QoQ) | +3.83% |
| Owned by Insiders (%) | 2.54% |
| Owned by Institutions (%) | 35.35% |
| Float | 33.72M |
Valuation Ratios
The trailing PE ratio is 240.14 and the forward PE ratio is 9.57.
| PE Ratio | 240.14 |
| Forward PE | 9.57 |
| PS Ratio | 0.78 |
| Forward PS | 0.76 |
| PB Ratio | 2.76 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.14 |
| P/OCF Ratio | 12.37 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.56, with an EV/FCF ratio of 22.76.
| EV / Earnings | 418.97 |
| EV / Sales | 1.38 |
| EV / EBITDA | 12.56 |
| EV / EBIT | 17.79 |
| EV / FCF | 22.76 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 1.79.
| Current Ratio | 1.48 |
| Quick Ratio | 0.89 |
| Debt / Equity | 1.79 |
| Debt / EBITDA | 5.39 |
| Debt / FCF | 10.58 |
| Interest Coverage | 1.30 |
Financial Efficiency
Return on equity (ROE) is 1.39% and return on invested capital (ROIC) is 4.71%.
| Return on Equity (ROE) | 1.39% |
| Return on Assets (ROA) | 3.64% |
| Return on Invested Capital (ROIC) | 4.71% |
| Return on Capital Employed (ROCE) | 8.37% |
| Revenue Per Employee | $606,604 |
| Profits Per Employee | $1,991 |
| Employee Count | 930 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 1.99 |
Taxes
In the past 12 months, Bioventus has paid $2.09 million in taxes.
| Income Tax | 2.09M |
| Effective Tax Rate | 43.44% |
Stock Price Statistics
The stock price has decreased by -43.40% in the last 52 weeks. The beta is 0.81, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -43.40% |
| 50-Day Moving Average | 7.00 |
| 200-Day Moving Average | 8.06 |
| Relative Strength Index (RSI) | 42.78 |
| Average Volume (20 Days) | 305,566 |
Short Selling Information
The latest short interest is 1.93 million, so 2.88% of the outstanding shares have been sold short.
| Short Interest | 1.93M |
| Short Previous Month | 1.84M |
| Short % of Shares Out | 2.88% |
| Short % of Float | 5.71% |
| Short Ratio (days to cover) | 5.02 |
Income Statement
In the last 12 months, Bioventus had revenue of $564.14 million and earned $1.85 million in profits. Earnings per share was $0.03.
| Revenue | 564.14M |
| Gross Profit | 381.35M |
| Operating Income | 43.61M |
| Pretax Income | 4.80M |
| Net Income | 1.85M |
| EBITDA | 61.78M |
| EBIT | 43.61M |
| Earnings Per Share (EPS) | $0.03 |
Balance Sheet
The company has $32.91 million in cash and $360.66 million in debt, giving a net cash position of -$327.75 million or -$4.90 per share.
| Cash & Cash Equivalents | 32.91M |
| Total Debt | 360.66M |
| Net Cash | -327.75M |
| Net Cash Per Share | -$4.90 |
| Equity (Book Value) | 201.30M |
| Book Value Per Share | 2.41 |
| Working Capital | 89.52M |
Cash Flow
In the last 12 months, operating cash flow was $36.25 million and capital expenditures -$2.15 million, giving a free cash flow of $34.10 million.
| Operating Cash Flow | 36.25M |
| Capital Expenditures | -2.15M |
| Free Cash Flow | 34.10M |
| FCF Per Share | $0.51 |
Margins
Gross margin is 67.60%, with operating and profit margins of 7.73% and 0.33%.
| Gross Margin | 67.60% |
| Operating Margin | 7.73% |
| Pretax Margin | 0.85% |
| Profit Margin | 0.33% |
| EBITDA Margin | 10.95% |
| EBIT Margin | 7.73% |
| FCF Margin | 6.04% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.89% |
| Shareholder Yield | -5.89% |
| Earnings Yield | 0.41% |
| FCF Yield | 7.61% |
Analyst Forecast
The average price target for Bioventus is $13.75, which is 105.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.75 |
| Price Target Difference | 105.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 1.19 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.19 |
| Piotroski F-Score | 8 |